Investor Relations

Corporate Profile

Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. 
 
Urovant recently reported positive long-term data for its lead product candidate, vibegron, an oral, once-daily small molecule beta-3 agonist being evaluated for overactive bladder (OAB). The extension of the 12-week pivotal phase 3 EMPOWUR study demonstrated a favorable long-term safety and tolerability profile for vibegron and further improved treatment benefit on key overactive bladder (OAB) symptoms over the 40-week extension period. 
 
Vibegron is also being evaluated in a phase 3 study for the treatment of OAB in men with benign prostatic hyperplasia and in a phase 2a study for abdominal pain associated with irritable bowel syndrome. 
 
Urovant’s second product candidate, URO-902, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacological therapy and Urovant Sciences intends to develop novel treatments for additional urologic diseases.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases
May 27, 2020
Urovant Sciences Appoints James Hindman to Board of Directors
James Hindman , a veteran global and strategic senior financial executive, brings extensive experience in the pharmaceutical, biologics and medical device industries to the Urovant Board Mr. Hindman most recently served as Chief Financial Officer at Allergan until its $70.5B sale to Actavis IRVINE,
Additional Formats
May 14, 2020
Urovant Sciences Presents Positive Clinical Efficacy & Safety Data on Lead Drug Candidate Vibegron at Virtual American Urological Association Annual Meeting
52-Week Post Hoc Analysis Shows Vibegron Patients Had Statistically Significant, Sustained Reduction in UUI and Total Incontinence Episodes Compared to Active Control IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--May 14, 2020-- Urovant Sciences (Nasdaq: UROV) announced today that data from
Additional Formats